nodes	percent_of_prediction	percent_of_DWPC	metapath
Framycetin—CXCR4—hematologic cancer	0.716	1	CbGaD
Framycetin—CXCR4—hematopoietic system—hematologic cancer	0.00561	0.261	CbGeAlD
Framycetin—CXCR4—blood—hematologic cancer	0.00372	0.173	CbGeAlD
Framycetin—CXCR4—bone marrow—hematologic cancer	0.0036	0.167	CbGeAlD
Framycetin—CXCR4—lung—hematologic cancer	0.00326	0.152	CbGeAlD
Framycetin—CXCR4—testis—hematologic cancer	0.00308	0.143	CbGeAlD
Framycetin—CXCR4—lymph node—hematologic cancer	0.00223	0.104	CbGeAlD
Framycetin—Hypersensitivity—Idarubicin—hematologic cancer	0.000202	0.00152	CcSEcCtD
Framycetin—Viral infection—Epirubicin—hematologic cancer	0.000202	0.00152	CcSEcCtD
Framycetin—Pruritus—Anagrelide—hematologic cancer	0.000201	0.00151	CcSEcCtD
Framycetin—Pruritus—Pentostatin—hematologic cancer	0.000201	0.00151	CcSEcCtD
Framycetin—Diarrhoea—Mercaptopurine—hematologic cancer	0.000198	0.00149	CcSEcCtD
Framycetin—Erythema—Thiotepa—hematologic cancer	0.000198	0.00149	CcSEcCtD
Framycetin—Hypersensitivity—Teniposide—hematologic cancer	0.000196	0.00148	CcSEcCtD
Framycetin—Diarrhoea—Clofarabine—hematologic cancer	0.000195	0.00147	CcSEcCtD
Framycetin—Diarrhoea—Daunorubicin—hematologic cancer	0.000195	0.00147	CcSEcCtD
Framycetin—Diarrhoea—Pentostatin—hematologic cancer	0.000194	0.00146	CcSEcCtD
Framycetin—Diarrhoea—Anagrelide—hematologic cancer	0.000194	0.00146	CcSEcCtD
Framycetin—Vomiting—Nelarabine—hematologic cancer	0.000194	0.00146	CcSEcCtD
Framycetin—Anaphylactic shock—Melphalan—hematologic cancer	0.000193	0.00145	CcSEcCtD
Framycetin—Infection—Melphalan—hematologic cancer	0.000192	0.00144	CcSEcCtD
Framycetin—Pruritus—Teniposide—hematologic cancer	0.000189	0.00142	CcSEcCtD
Framycetin—Diarrhoea—Idarubicin—hematologic cancer	0.000188	0.00141	CcSEcCtD
Framycetin—Infection—Lenalidomide—hematologic cancer	0.000187	0.0014	CcSEcCtD
Framycetin—Viral infection—Doxorubicin—hematologic cancer	0.000187	0.0014	CcSEcCtD
Framycetin—Infection—Hydroxyurea—hematologic cancer	0.000184	0.00138	CcSEcCtD
Framycetin—Vomiting—Mercaptopurine—hematologic cancer	0.000184	0.00138	CcSEcCtD
Framycetin—Erythema—Carmustine—hematologic cancer	0.000184	0.00138	CcSEcCtD
Framycetin—Diarrhoea—Teniposide—hematologic cancer	0.000182	0.00137	CcSEcCtD
Framycetin—Hypersensitivity—Busulfan—hematologic cancer	0.000182	0.00137	CcSEcCtD
Framycetin—Erythema—Alitretinoin—hematologic cancer	0.000182	0.00137	CcSEcCtD
Framycetin—Vomiting—Daunorubicin—hematologic cancer	0.000182	0.00136	CcSEcCtD
Framycetin—Vomiting—Clofarabine—hematologic cancer	0.000182	0.00136	CcSEcCtD
Framycetin—Nausea—Nelarabine—hematologic cancer	0.000181	0.00136	CcSEcCtD
Framycetin—Vomiting—Pentostatin—hematologic cancer	0.000181	0.00136	CcSEcCtD
Framycetin—Vomiting—Anagrelide—hematologic cancer	0.000181	0.00136	CcSEcCtD
Framycetin—Erythema—Ifosfamide—hematologic cancer	0.00018	0.00135	CcSEcCtD
Framycetin—Nausea—Methoxsalen—hematologic cancer	0.000177	0.00133	CcSEcCtD
Framycetin—Hypersensitivity—Procarbazine—hematologic cancer	0.000177	0.00133	CcSEcCtD
Framycetin—Pruritus—Busulfan—hematologic cancer	0.000175	0.00131	CcSEcCtD
Framycetin—Vomiting—Idarubicin—hematologic cancer	0.000174	0.00131	CcSEcCtD
Framycetin—Anaphylactic shock—Bortezomib—hematologic cancer	0.000173	0.0013	CcSEcCtD
Framycetin—Hypersensitivity—Bexarotene—hematologic cancer	0.000173	0.0013	CcSEcCtD
Framycetin—Hypersensitivity—Dasatinib—hematologic cancer	0.000173	0.0013	CcSEcCtD
Framycetin—Hypersensitivity—Fludarabine—hematologic cancer	0.000173	0.0013	CcSEcCtD
Framycetin—Infection—Bortezomib—hematologic cancer	0.000172	0.00129	CcSEcCtD
Framycetin—Nausea—Mercaptopurine—hematologic cancer	0.000172	0.00129	CcSEcCtD
Framycetin—Anaphylactic shock—Bleomycin—hematologic cancer	0.000172	0.00129	CcSEcCtD
Framycetin—Erythema—Mitoxantrone—hematologic cancer	0.000171	0.00128	CcSEcCtD
Framycetin—Infection—Bleomycin—hematologic cancer	0.000171	0.00128	CcSEcCtD
Framycetin—Pruritus—Procarbazine—hematologic cancer	0.00017	0.00127	CcSEcCtD
Framycetin—Nausea—Clofarabine—hematologic cancer	0.00017	0.00127	CcSEcCtD
Framycetin—Nausea—Daunorubicin—hematologic cancer	0.00017	0.00127	CcSEcCtD
Framycetin—Vomiting—Teniposide—hematologic cancer	0.00017	0.00127	CcSEcCtD
Framycetin—Diarrhoea—Busulfan—hematologic cancer	0.000169	0.00127	CcSEcCtD
Framycetin—Anaphylactic shock—Vinorelbine—hematologic cancer	0.000169	0.00127	CcSEcCtD
Framycetin—Nausea—Pentostatin—hematologic cancer	0.000169	0.00127	CcSEcCtD
Framycetin—Nausea—Anagrelide—hematologic cancer	0.000169	0.00127	CcSEcCtD
Framycetin—Infection—Vinorelbine—hematologic cancer	0.000168	0.00126	CcSEcCtD
Framycetin—Erythema—Gemcitabine—hematologic cancer	0.000166	0.00125	CcSEcCtD
Framycetin—Pruritus—Bexarotene—hematologic cancer	0.000166	0.00125	CcSEcCtD
Framycetin—Pruritus—Dasatinib—hematologic cancer	0.000166	0.00125	CcSEcCtD
Framycetin—Pruritus—Fludarabine—hematologic cancer	0.000166	0.00125	CcSEcCtD
Framycetin—Diarrhoea—Procarbazine—hematologic cancer	0.000164	0.00123	CcSEcCtD
Framycetin—Hypersensitivity—Chlorambucil—hematologic cancer	0.000164	0.00123	CcSEcCtD
Framycetin—Nausea—Idarubicin—hematologic cancer	0.000163	0.00122	CcSEcCtD
Framycetin—Diarrhoea—Bexarotene—hematologic cancer	0.000161	0.00121	CcSEcCtD
Framycetin—Diarrhoea—Dasatinib—hematologic cancer	0.000161	0.00121	CcSEcCtD
Framycetin—Infection—Thiotepa—hematologic cancer	0.00016	0.0012	CcSEcCtD
Framycetin—Diarrhoea—Fludarabine—hematologic cancer	0.00016	0.0012	CcSEcCtD
Framycetin—Hypersensitivity—Nilotinib—hematologic cancer	0.00016	0.0012	CcSEcCtD
Framycetin—Hypersensitivity—Imatinib—hematologic cancer	0.000159	0.00119	CcSEcCtD
Framycetin—Nausea—Teniposide—hematologic cancer	0.000158	0.00119	CcSEcCtD
Framycetin—Vomiting—Busulfan—hematologic cancer	0.000157	0.00118	CcSEcCtD
Framycetin—Pruritus—Chlorambucil—hematologic cancer	0.000157	0.00118	CcSEcCtD
Framycetin—Hypersensitivity—Cladribine—hematologic cancer	0.000156	0.00117	CcSEcCtD
Framycetin—Infection—Thalidomide—hematologic cancer	0.000155	0.00117	CcSEcCtD
Framycetin—Erythema—Cisplatin—hematologic cancer	0.000155	0.00117	CcSEcCtD
Framycetin—Pruritus—Nilotinib—hematologic cancer	0.000154	0.00115	CcSEcCtD
Framycetin—Pruritus—Imatinib—hematologic cancer	0.000153	0.00115	CcSEcCtD
Framycetin—Vomiting—Procarbazine—hematologic cancer	0.000152	0.00114	CcSEcCtD
Framycetin—Diarrhoea—Chlorambucil—hematologic cancer	0.000152	0.00114	CcSEcCtD
Framycetin—Pruritus—Cladribine—hematologic cancer	0.00015	0.00113	CcSEcCtD
Framycetin—Hypersensitivity—Vinblastine—hematologic cancer	0.00015	0.00113	CcSEcCtD
Framycetin—Vomiting—Bexarotene—hematologic cancer	0.000149	0.00112	CcSEcCtD
Framycetin—Vomiting—Dasatinib—hematologic cancer	0.000149	0.00112	CcSEcCtD
Framycetin—Infection—Carmustine—hematologic cancer	0.000149	0.00112	CcSEcCtD
Framycetin—Vomiting—Fludarabine—hematologic cancer	0.000149	0.00112	CcSEcCtD
Framycetin—Anaphylactic shock—Alitretinoin—hematologic cancer	0.000149	0.00112	CcSEcCtD
Framycetin—Diarrhoea—Nilotinib—hematologic cancer	0.000149	0.00112	CcSEcCtD
Framycetin—Diarrhoea—Imatinib—hematologic cancer	0.000148	0.00111	CcSEcCtD
Framycetin—Infection—Alitretinoin—hematologic cancer	0.000148	0.00111	CcSEcCtD
Framycetin—Anaphylactic shock—Ifosfamide—hematologic cancer	0.000147	0.0011	CcSEcCtD
Framycetin—Nausea—Busulfan—hematologic cancer	0.000147	0.0011	CcSEcCtD
Framycetin—Infection—Ifosfamide—hematologic cancer	0.000146	0.0011	CcSEcCtD
Framycetin—Diarrhoea—Cladribine—hematologic cancer	0.000145	0.00109	CcSEcCtD
Framycetin—Anaphylactic shock—Vincristine—hematologic cancer	0.000143	0.00108	CcSEcCtD
Framycetin—Hypersensitivity—Melphalan—hematologic cancer	0.000143	0.00107	CcSEcCtD
Framycetin—Nausea—Procarbazine—hematologic cancer	0.000142	0.00107	CcSEcCtD
Framycetin—Infection—Vincristine—hematologic cancer	0.000142	0.00107	CcSEcCtD
Framycetin—Vomiting—Chlorambucil—hematologic cancer	0.000141	0.00106	CcSEcCtD
Framycetin—Erythema—Prednisolone—hematologic cancer	0.00014	0.00105	CcSEcCtD
Framycetin—Nausea—Bexarotene—hematologic cancer	0.00014	0.00105	CcSEcCtD
Framycetin—Nausea—Dasatinib—hematologic cancer	0.00014	0.00105	CcSEcCtD
Framycetin—Anaphylactic shock—Irinotecan—hematologic cancer	0.000139	0.00105	CcSEcCtD
Framycetin—Anaphylactic shock—Mitoxantrone—hematologic cancer	0.000139	0.00105	CcSEcCtD
Framycetin—Nausea—Fludarabine—hematologic cancer	0.000139	0.00105	CcSEcCtD
Framycetin—Diarrhoea—Vinblastine—hematologic cancer	0.000139	0.00105	CcSEcCtD
Framycetin—Hypersensitivity—Lenalidomide—hematologic cancer	0.000139	0.00104	CcSEcCtD
Framycetin—Infection—Irinotecan—hematologic cancer	0.000139	0.00104	CcSEcCtD
Framycetin—Infection—Mitoxantrone—hematologic cancer	0.000139	0.00104	CcSEcCtD
Framycetin—Vomiting—Nilotinib—hematologic cancer	0.000138	0.00104	CcSEcCtD
Framycetin—Vomiting—Imatinib—hematologic cancer	0.000137	0.00103	CcSEcCtD
Framycetin—Pruritus—Melphalan—hematologic cancer	0.000137	0.00103	CcSEcCtD
Framycetin—Hypersensitivity—Hydroxyurea—hematologic cancer	0.000137	0.00103	CcSEcCtD
Framycetin—Anaphylactic shock—Gemcitabine—hematologic cancer	0.000136	0.00102	CcSEcCtD
Framycetin—Infection—Gemcitabine—hematologic cancer	0.000135	0.00101	CcSEcCtD
Framycetin—Vomiting—Cladribine—hematologic cancer	0.000135	0.00101	CcSEcCtD
Framycetin—Pruritus—Lenalidomide—hematologic cancer	0.000133	0.001	CcSEcCtD
Framycetin—Diarrhoea—Melphalan—hematologic cancer	0.000132	0.000994	CcSEcCtD
Framycetin—Nausea—Chlorambucil—hematologic cancer	0.000132	0.00099	CcSEcCtD
Framycetin—Vomiting—Vinblastine—hematologic cancer	0.000129	0.000972	CcSEcCtD
Framycetin—Nausea—Nilotinib—hematologic cancer	0.000129	0.000969	CcSEcCtD
Framycetin—Erythema—Triamcinolone—hematologic cancer	0.000129	0.000968	CcSEcCtD
Framycetin—Diarrhoea—Lenalidomide—hematologic cancer	0.000129	0.000967	CcSEcCtD
Framycetin—Nausea—Imatinib—hematologic cancer	0.000128	0.000963	CcSEcCtD
Framycetin—Hypersensitivity—Bortezomib—hematologic cancer	0.000128	0.000958	CcSEcCtD
Framycetin—Diarrhoea—Hydroxyurea—hematologic cancer	0.000127	0.000953	CcSEcCtD
Framycetin—Anaphylactic shock—Cisplatin—hematologic cancer	0.000127	0.000951	CcSEcCtD
Framycetin—Hypersensitivity—Bleomycin—hematologic cancer	0.000127	0.000951	CcSEcCtD
Framycetin—Nausea—Cladribine—hematologic cancer	0.000126	0.000946	CcSEcCtD
Framycetin—Infection—Cisplatin—hematologic cancer	0.000126	0.000945	CcSEcCtD
Framycetin—Hypersensitivity—Vinorelbine—hematologic cancer	0.000125	0.000936	CcSEcCtD
Framycetin—Vomiting—Melphalan—hematologic cancer	0.000123	0.000924	CcSEcCtD
Framycetin—Pruritus—Bortezomib—hematologic cancer	0.000122	0.00092	CcSEcCtD
Framycetin—Pruritus—Bleomycin—hematologic cancer	0.000122	0.000913	CcSEcCtD
Framycetin—Nausea—Vinblastine—hematologic cancer	0.000121	0.000908	CcSEcCtD
Framycetin—Vomiting—Lenalidomide—hematologic cancer	0.00012	0.000899	CcSEcCtD
Framycetin—Pruritus—Vinorelbine—hematologic cancer	0.00012	0.000898	CcSEcCtD
Framycetin—Hypersensitivity—Thiotepa—hematologic cancer	0.000119	0.000893	CcSEcCtD
Framycetin—Diarrhoea—Bortezomib—hematologic cancer	0.000118	0.00089	CcSEcCtD
Framycetin—Vomiting—Hydroxyurea—hematologic cancer	0.000118	0.000886	CcSEcCtD
Framycetin—Erythema—Dexamethasone—hematologic cancer	0.000117	0.000878	CcSEcCtD
Framycetin—Erythema—Betamethasone—hematologic cancer	0.000117	0.000878	CcSEcCtD
Framycetin—Anaphylactic shock—Etoposide—hematologic cancer	0.000116	0.000871	CcSEcCtD
Framycetin—Diarrhoea—Vinorelbine—hematologic cancer	0.000116	0.000869	CcSEcCtD
Framycetin—Infection—Etoposide—hematologic cancer	0.000115	0.000865	CcSEcCtD
Framycetin—Hypersensitivity—Thalidomide—hematologic cancer	0.000115	0.000864	CcSEcCtD
Framycetin—Nausea—Melphalan—hematologic cancer	0.000115	0.000863	CcSEcCtD
Framycetin—Anaphylactic shock—Prednisolone—hematologic cancer	0.000114	0.000859	CcSEcCtD
Framycetin—Pruritus—Thiotepa—hematologic cancer	0.000114	0.000858	CcSEcCtD
Framycetin—Nausea—Lenalidomide—hematologic cancer	0.000112	0.000839	CcSEcCtD
Framycetin—Hypersensitivity—Carmustine—hematologic cancer	0.00011	0.00083	CcSEcCtD
Framycetin—Pruritus—Thalidomide—hematologic cancer	0.00011	0.00083	CcSEcCtD
Framycetin—Diarrhoea—Thiotepa—hematologic cancer	0.00011	0.00083	CcSEcCtD
Framycetin—Nausea—Hydroxyurea—hematologic cancer	0.00011	0.000828	CcSEcCtD
Framycetin—Vomiting—Bortezomib—hematologic cancer	0.00011	0.000827	CcSEcCtD
Framycetin—Hypersensitivity—Alitretinoin—hematologic cancer	0.000109	0.000822	CcSEcCtD
Framycetin—Vomiting—Bleomycin—hematologic cancer	0.000109	0.000821	CcSEcCtD
Framycetin—Hypersensitivity—Ifosfamide—hematologic cancer	0.000108	0.000813	CcSEcCtD
Framycetin—Vomiting—Vinorelbine—hematologic cancer	0.000107	0.000807	CcSEcCtD
Framycetin—Diarrhoea—Thalidomide—hematologic cancer	0.000107	0.000803	CcSEcCtD
Framycetin—Hypersensitivity—Vincristine—hematologic cancer	0.000105	0.000792	CcSEcCtD
Framycetin—Anaphylactic shock—Triamcinolone—hematologic cancer	0.000105	0.00079	CcSEcCtD
Framycetin—Pruritus—Alitretinoin—hematologic cancer	0.000105	0.00079	CcSEcCtD
Framycetin—Infection—Triamcinolone—hematologic cancer	0.000104	0.000785	CcSEcCtD
Framycetin—Pruritus—Ifosfamide—hematologic cancer	0.000104	0.00078	CcSEcCtD
Framycetin—Nausea—Bortezomib—hematologic cancer	0.000103	0.000772	CcSEcCtD
Framycetin—Hypersensitivity—Irinotecan—hematologic cancer	0.000103	0.000772	CcSEcCtD
Framycetin—Hypersensitivity—Mitoxantrone—hematologic cancer	0.000103	0.000772	CcSEcCtD
Framycetin—Vomiting—Thiotepa—hematologic cancer	0.000103	0.000771	CcSEcCtD
Framycetin—Diarrhoea—Carmustine—hematologic cancer	0.000103	0.000771	CcSEcCtD
Framycetin—Nausea—Bleomycin—hematologic cancer	0.000102	0.000767	CcSEcCtD
Framycetin—Erythema—Prednisone—hematologic cancer	0.000102	0.000765	CcSEcCtD
Framycetin—Diarrhoea—Alitretinoin—hematologic cancer	0.000102	0.000764	CcSEcCtD
Framycetin—Diarrhoea—Ifosfamide—hematologic cancer	0.0001	0.000755	CcSEcCtD
Framycetin—Nausea—Vinorelbine—hematologic cancer	0.0001	0.000754	CcSEcCtD
Framycetin—Vomiting—Thalidomide—hematologic cancer	9.93e-05	0.000746	CcSEcCtD
Framycetin—Diarrhoea—Vincristine—hematologic cancer	9.79e-05	0.000736	CcSEcCtD
Framycetin—Pruritus—Gemcitabine—hematologic cancer	9.61e-05	0.000722	CcSEcCtD
Framycetin—Nausea—Thiotepa—hematologic cancer	9.59e-05	0.00072	CcSEcCtD
Framycetin—Anaphylactic shock—Dexamethasone—hematologic cancer	9.54e-05	0.000717	CcSEcCtD
Framycetin—Anaphylactic shock—Betamethasone—hematologic cancer	9.54e-05	0.000717	CcSEcCtD
Framycetin—Diarrhoea—Mitoxantrone—hematologic cancer	9.54e-05	0.000717	CcSEcCtD
Framycetin—Diarrhoea—Irinotecan—hematologic cancer	9.54e-05	0.000717	CcSEcCtD
Framycetin—Vomiting—Carmustine—hematologic cancer	9.54e-05	0.000716	CcSEcCtD
Framycetin—Infection—Dexamethasone—hematologic cancer	9.48e-05	0.000712	CcSEcCtD
Framycetin—Infection—Betamethasone—hematologic cancer	9.48e-05	0.000712	CcSEcCtD
Framycetin—Vomiting—Alitretinoin—hematologic cancer	9.45e-05	0.00071	CcSEcCtD
Framycetin—Vomiting—Ifosfamide—hematologic cancer	9.34e-05	0.000701	CcSEcCtD
Framycetin—Hypersensitivity—Cisplatin—hematologic cancer	9.33e-05	0.000701	CcSEcCtD
Framycetin—Diarrhoea—Gemcitabine—hematologic cancer	9.29e-05	0.000698	CcSEcCtD
Framycetin—Nausea—Thalidomide—hematologic cancer	9.27e-05	0.000697	CcSEcCtD
Framycetin—Vomiting—Vincristine—hematologic cancer	9.1e-05	0.000684	CcSEcCtD
Framycetin—Nausea—Carmustine—hematologic cancer	8.91e-05	0.000669	CcSEcCtD
Framycetin—Vomiting—Irinotecan—hematologic cancer	8.86e-05	0.000666	CcSEcCtD
Framycetin—Vomiting—Mitoxantrone—hematologic cancer	8.86e-05	0.000666	CcSEcCtD
Framycetin—Nausea—Alitretinoin—hematologic cancer	8.82e-05	0.000663	CcSEcCtD
Framycetin—Nausea—Ifosfamide—hematologic cancer	8.72e-05	0.000655	CcSEcCtD
Framycetin—Diarrhoea—Cisplatin—hematologic cancer	8.66e-05	0.000651	CcSEcCtD
Framycetin—Vomiting—Gemcitabine—hematologic cancer	8.63e-05	0.000649	CcSEcCtD
Framycetin—Hypersensitivity—Etoposide—hematologic cancer	8.54e-05	0.000642	CcSEcCtD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCL2—hematologic cancer	8.52e-05	0.000659	CbGpPWpGaD
Framycetin—Erythema—Methotrexate—hematologic cancer	8.51e-05	0.000639	CcSEcCtD
Framycetin—Nausea—Vincristine—hematologic cancer	8.5e-05	0.000639	CcSEcCtD
Framycetin—Hypersensitivity—Prednisolone—hematologic cancer	8.43e-05	0.000633	CcSEcCtD
Framycetin—CXCR4—Disease—IDH1—hematologic cancer	8.31e-05	0.000643	CbGpPWpGaD
Framycetin—Anaphylactic shock—Prednisone—hematologic cancer	8.31e-05	0.000624	CcSEcCtD
Framycetin—Nausea—Mitoxantrone—hematologic cancer	8.28e-05	0.000622	CcSEcCtD
Framycetin—Nausea—Irinotecan—hematologic cancer	8.28e-05	0.000622	CcSEcCtD
Framycetin—Infection—Prednisone—hematologic cancer	8.26e-05	0.00062	CcSEcCtD
Framycetin—CXCR4—Disease—GSTO1—hematologic cancer	8.22e-05	0.000636	CbGpPWpGaD
Framycetin—Pruritus—Etoposide—hematologic cancer	8.2e-05	0.000616	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—ARHGEF12—hematologic cancer	8.17e-05	0.000632	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—ADCY7—hematologic cancer	8.17e-05	0.000632	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—PTHLH—hematologic cancer	8.13e-05	0.000629	CbGpPWpGaD
Framycetin—Nausea—Gemcitabine—hematologic cancer	8.07e-05	0.000606	CcSEcCtD
Framycetin—Vomiting—Cisplatin—hematologic cancer	8.05e-05	0.000605	CcSEcCtD
Framycetin—CXCR4—Disease—AGO2—hematologic cancer	8.04e-05	0.000622	CbGpPWpGaD
Framycetin—Erythema—Epirubicin—hematologic cancer	7.97e-05	0.000598	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—ARHGEF1—hematologic cancer	7.96e-05	0.000616	CbGpPWpGaD
Framycetin—CXCR4—Disease—HDAC9—hematologic cancer	7.96e-05	0.000616	CbGpPWpGaD
Framycetin—Diarrhoea—Etoposide—hematologic cancer	7.93e-05	0.000596	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—PTGER4—hematologic cancer	7.92e-05	0.000612	CbGpPWpGaD
Framycetin—CXCR4—Disease—H3F3B—hematologic cancer	7.88e-05	0.00061	CbGpPWpGaD
Framycetin—Hypersensitivity—Triamcinolone—hematologic cancer	7.75e-05	0.000582	CcSEcCtD
Framycetin—CXCR4—Disease—NPM1—hematologic cancer	7.59e-05	0.000587	CbGpPWpGaD
Framycetin—Nausea—Cisplatin—hematologic cancer	7.52e-05	0.000565	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—CCL3—hematologic cancer	7.47e-05	0.000578	CbGpPWpGaD
Framycetin—Pruritus—Triamcinolone—hematologic cancer	7.44e-05	0.000559	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—PTHLH—hematologic cancer	7.39e-05	0.000571	CbGpPWpGaD
Framycetin—Vomiting—Etoposide—hematologic cancer	7.37e-05	0.000554	CcSEcCtD
Framycetin—Erythema—Doxorubicin—hematologic cancer	7.37e-05	0.000554	CcSEcCtD
Framycetin—CXCR4—Disease—FGF19—hematologic cancer	7.27e-05	0.000562	CbGpPWpGaD
Framycetin—CXCR4—Disease—RPS14—hematologic cancer	7.21e-05	0.000558	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—PTGER4—hematologic cancer	7.19e-05	0.000556	CbGpPWpGaD
Framycetin—CXCR4—Disease—DKK1—hematologic cancer	7.15e-05	0.000553	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—AGRN—hematologic cancer	7.14e-05	0.000552	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CCL17—hematologic cancer	7.14e-05	0.000552	CbGpPWpGaD
Framycetin—CXCR4—Disease—STAT5B—hematologic cancer	7.1e-05	0.000549	CbGpPWpGaD
Framycetin—CXCR4—Disease—NUP98—hematologic cancer	7.1e-05	0.000549	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CXCR5—hematologic cancer	7.01e-05	0.000542	CbGpPWpGaD
Framycetin—Anaphylactic shock—Methotrexate—hematologic cancer	6.95e-05	0.000522	CcSEcCtD
Framycetin—CXCR4—Disease—CST3—hematologic cancer	6.94e-05	0.000537	CbGpPWpGaD
Framycetin—Infection—Methotrexate—hematologic cancer	6.9e-05	0.000518	CcSEcCtD
Framycetin—CXCR4—Disease—ADCY7—hematologic cancer	6.89e-05	0.000533	CbGpPWpGaD
Framycetin—Nausea—Etoposide—hematologic cancer	6.89e-05	0.000517	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—LEF1—hematologic cancer	6.89e-05	0.000533	CbGpPWpGaD
Framycetin—CXCR4—Disease—NUP214—hematologic cancer	6.84e-05	0.000529	CbGpPWpGaD
Framycetin—Nausea—Prednisolone—hematologic cancer	6.79e-05	0.00051	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—GNA13—hematologic cancer	6.77e-05	0.000524	CbGpPWpGaD
Framycetin—Pruritus—Betamethasone—hematologic cancer	6.75e-05	0.000507	CcSEcCtD
Framycetin—Pruritus—Dexamethasone—hematologic cancer	6.75e-05	0.000507	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—IL3—hematologic cancer	6.74e-05	0.000522	CbGpPWpGaD
Framycetin—CXCR4—Disease—XIAP—hematologic cancer	6.7e-05	0.000518	CbGpPWpGaD
Framycetin—CXCR4—Disease—MTR—hematologic cancer	6.7e-05	0.000518	CbGpPWpGaD
Framycetin—Vomiting—Triamcinolone—hematologic cancer	6.69e-05	0.000502	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—TIAM1—hematologic cancer	6.66e-05	0.000515	CbGpPWpGaD
Framycetin—CXCR4—Disease—ENO2—hematologic cancer	6.57e-05	0.000508	CbGpPWpGaD
Framycetin—CXCR4—Disease—SMARCA4—hematologic cancer	6.53e-05	0.000505	CbGpPWpGaD
Framycetin—Diarrhoea—Dexamethasone—hematologic cancer	6.53e-05	0.000491	CcSEcCtD
Framycetin—Diarrhoea—Betamethasone—hematologic cancer	6.53e-05	0.000491	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—RASGRP1—hematologic cancer	6.52e-05	0.000505	CbGpPWpGaD
Framycetin—Anaphylactic shock—Epirubicin—hematologic cancer	6.5e-05	0.000488	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—CCL2—hematologic cancer	6.49e-05	0.000502	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—JAK3—hematologic cancer	6.46e-05	0.0005	CbGpPWpGaD
Framycetin—Infection—Epirubicin—hematologic cancer	6.46e-05	0.000485	CcSEcCtD
Framycetin—Nausea—Triamcinolone—hematologic cancer	6.25e-05	0.000469	CcSEcCtD
Framycetin—CXCR4—Disease—SDC1—hematologic cancer	6.23e-05	0.000482	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CXCL13—hematologic cancer	6.19e-05	0.000479	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CCR7—hematologic cancer	6.19e-05	0.000479	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—IL3—hematologic cancer	6.12e-05	0.000474	CbGpPWpGaD
Framycetin—Hypersensitivity—Prednisone—hematologic cancer	6.12e-05	0.00046	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—NCOR2—hematologic cancer	6.11e-05	0.000473	CbGpPWpGaD
Framycetin—Vomiting—Dexamethasone—hematologic cancer	6.07e-05	0.000456	CcSEcCtD
Framycetin—Vomiting—Betamethasone—hematologic cancer	6.07e-05	0.000456	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—IL3RA—hematologic cancer	6.03e-05	0.000467	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CRKL—hematologic cancer	6.03e-05	0.000467	CbGpPWpGaD
Framycetin—CXCR4—Disease—LCK—hematologic cancer	6.03e-05	0.000467	CbGpPWpGaD
Framycetin—Anaphylactic shock—Doxorubicin—hematologic cancer	6.01e-05	0.000452	CcSEcCtD
Framycetin—Infection—Doxorubicin—hematologic cancer	5.98e-05	0.000449	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—RASGRP1—hematologic cancer	5.92e-05	0.000458	CbGpPWpGaD
Framycetin—CXCR4—Disease—H3F3A—hematologic cancer	5.91e-05	0.000458	CbGpPWpGaD
Framycetin—Pruritus—Prednisone—hematologic cancer	5.88e-05	0.000442	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—GRB2—hematologic cancer	5.87e-05	0.000454	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—RGS2—hematologic cancer	5.82e-05	0.00045	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—TRIO—hematologic cancer	5.76e-05	0.000445	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CMA1—hematologic cancer	5.76e-05	0.000445	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—TRH—hematologic cancer	5.76e-05	0.000445	CbGpPWpGaD
Framycetin—CXCR4—Disease—PRKCZ—hematologic cancer	5.75e-05	0.000445	CbGpPWpGaD
Framycetin—Diarrhoea—Prednisone—hematologic cancer	5.69e-05	0.000427	CcSEcCtD
Framycetin—Nausea—Dexamethasone—hematologic cancer	5.67e-05	0.000426	CcSEcCtD
Framycetin—Nausea—Betamethasone—hematologic cancer	5.67e-05	0.000426	CcSEcCtD
Framycetin—CXCR4—Disease—CALR—hematologic cancer	5.65e-05	0.000437	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—AGO2—hematologic cancer	5.63e-05	0.000436	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—SPHK1—hematologic cancer	5.63e-05	0.000436	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—LPAR1—hematologic cancer	5.58e-05	0.000431	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—HDAC9—hematologic cancer	5.58e-05	0.000431	CbGpPWpGaD
Framycetin—CXCR4—Disease—PARP1—hematologic cancer	5.55e-05	0.00043	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—H3F3B—hematologic cancer	5.52e-05	0.000427	CbGpPWpGaD
Framycetin—CXCR4—Disease—FBXW7—hematologic cancer	5.46e-05	0.000423	CbGpPWpGaD
Framycetin—CXCR4—Disease—HDAC2—hematologic cancer	5.36e-05	0.000414	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—GRB2—hematologic cancer	5.33e-05	0.000412	CbGpPWpGaD
Framycetin—CXCR4—Disease—CD44—hematologic cancer	5.3e-05	0.00041	CbGpPWpGaD
Framycetin—Vomiting—Prednisone—hematologic cancer	5.28e-05	0.000397	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—CSF2—hematologic cancer	5.24e-05	0.000405	CbGpPWpGaD
Framycetin—CXCR4—Disease—CBL—hematologic cancer	5.22e-05	0.000404	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CNR2—hematologic cancer	5.13e-05	0.000397	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PDE4B—hematologic cancer	5.13e-05	0.000397	CbGpPWpGaD
Framycetin—Hypersensitivity—Methotrexate—hematologic cancer	5.12e-05	0.000384	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—FGF19—hematologic cancer	5.09e-05	0.000394	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—PRKCG—hematologic cancer	5.06e-05	0.000391	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—JAK1—hematologic cancer	5.06e-05	0.000391	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—RAC2—hematologic cancer	5.05e-05	0.000391	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—DKK1—hematologic cancer	5.01e-05	0.000387	CbGpPWpGaD
Framycetin—CXCR4—Disease—HSP90AA1—hematologic cancer	4.98e-05	0.000385	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—STAT5B—hematologic cancer	4.97e-05	0.000384	CbGpPWpGaD
Framycetin—Nausea—Prednisone—hematologic cancer	4.94e-05	0.000371	CcSEcCtD
Framycetin—Pruritus—Methotrexate—hematologic cancer	4.91e-05	0.000369	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—ADCY7—hematologic cancer	4.82e-05	0.000373	CbGpPWpGaD
Framycetin—CXCR4—Disease—STAT1—hematologic cancer	4.8e-05	0.000372	CbGpPWpGaD
Framycetin—Hypersensitivity—Epirubicin—hematologic cancer	4.79e-05	0.00036	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—CSF2—hematologic cancer	4.76e-05	0.000368	CbGpPWpGaD
Framycetin—Diarrhoea—Methotrexate—hematologic cancer	4.75e-05	0.000357	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—IL2RA—hematologic cancer	4.72e-05	0.000365	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—XIAP—hematologic cancer	4.69e-05	0.000363	CbGpPWpGaD
Framycetin—Pruritus—Epirubicin—hematologic cancer	4.6e-05	0.000345	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—JAK1—hematologic cancer	4.59e-05	0.000355	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—PRKCG—hematologic cancer	4.59e-05	0.000355	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—SMARCA4—hematologic cancer	4.57e-05	0.000354	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—SH2B3—hematologic cancer	4.57e-05	0.000354	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—GZMB—hematologic cancer	4.54e-05	0.000352	CbGpPWpGaD
Framycetin—CXCR4—Disease—GRB2—hematologic cancer	4.49e-05	0.000348	CbGpPWpGaD
Framycetin—CXCR4—Disease—PDGFA—hematologic cancer	4.48e-05	0.000347	CbGpPWpGaD
Framycetin—Diarrhoea—Epirubicin—hematologic cancer	4.45e-05	0.000334	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—CTNNA1—hematologic cancer	4.44e-05	0.000343	CbGpPWpGaD
Framycetin—Hypersensitivity—Doxorubicin—hematologic cancer	4.43e-05	0.000333	CcSEcCtD
Framycetin—CXCR4—Disease—KITLG—hematologic cancer	4.42e-05	0.000342	CbGpPWpGaD
Framycetin—Vomiting—Methotrexate—hematologic cancer	4.42e-05	0.000332	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—CCL3—hematologic cancer	4.41e-05	0.000341	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—EIF4EBP1—hematologic cancer	4.41e-05	0.000341	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—HSPB1—hematologic cancer	4.41e-05	0.000341	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PTHLH—hematologic cancer	4.36e-05	0.000338	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—SDC1—hematologic cancer	4.36e-05	0.000338	CbGpPWpGaD
Framycetin—CXCR4—Disease—STAT5A—hematologic cancer	4.32e-05	0.000334	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—IL2RA—hematologic cancer	4.29e-05	0.000332	CbGpPWpGaD
Framycetin—CXCR4—Disease—CDKN2B—hematologic cancer	4.28e-05	0.000331	CbGpPWpGaD
Framycetin—Pruritus—Doxorubicin—hematologic cancer	4.26e-05	0.00032	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—PTGER4—hematologic cancer	4.25e-05	0.000329	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—LCK—hematologic cancer	4.23e-05	0.000327	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—H3F3A—hematologic cancer	4.14e-05	0.00032	CbGpPWpGaD
Framycetin—CXCR4—Disease—CD86—hematologic cancer	4.14e-05	0.00032	CbGpPWpGaD
Framycetin—Vomiting—Epirubicin—hematologic cancer	4.13e-05	0.00031	CcSEcCtD
Framycetin—Nausea—Methotrexate—hematologic cancer	4.13e-05	0.00031	CcSEcCtD
Framycetin—Diarrhoea—Doxorubicin—hematologic cancer	4.12e-05	0.000309	CcSEcCtD
Framycetin—CXCR4—Disease—HES1—hematologic cancer	4.08e-05	0.000316	CbGpPWpGaD
Framycetin—CXCR4—Disease—NCOR1—hematologic cancer	4.06e-05	0.000314	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PRKCZ—hematologic cancer	4.03e-05	0.000311	CbGpPWpGaD
Framycetin—CXCR4—Disease—FGF1—hematologic cancer	4.01e-05	0.000311	CbGpPWpGaD
Framycetin—CXCR4—Disease—FOXO1—hematologic cancer	3.96e-05	0.000306	CbGpPWpGaD
Framycetin—CXCR4—Disease—PDGFRB—hematologic cancer	3.95e-05	0.000306	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—PIK3CG—hematologic cancer	3.94e-05	0.000304	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PARP1—hematologic cancer	3.89e-05	0.000301	CbGpPWpGaD
Framycetin—CXCR4—Disease—PDGFRA—hematologic cancer	3.89e-05	0.000301	CbGpPWpGaD
Framycetin—CXCR4—Disease—JAK1—hematologic cancer	3.87e-05	0.0003	CbGpPWpGaD
Framycetin—CXCR4—Disease—PRKCG—hematologic cancer	3.87e-05	0.0003	CbGpPWpGaD
Framycetin—Nausea—Epirubicin—hematologic cancer	3.86e-05	0.00029	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—FBXW7—hematologic cancer	3.83e-05	0.000296	CbGpPWpGaD
Framycetin—Vomiting—Doxorubicin—hematologic cancer	3.82e-05	0.000287	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—HDAC2—hematologic cancer	3.75e-05	0.00029	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CBL—hematologic cancer	3.66e-05	0.000283	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—IL3—hematologic cancer	3.62e-05	0.00028	CbGpPWpGaD
Framycetin—CXCR4—Disease—MTHFR—hematologic cancer	3.59e-05	0.000278	CbGpPWpGaD
Framycetin—CXCR4—Disease—TERT—hematologic cancer	3.58e-05	0.000277	CbGpPWpGaD
Framycetin—CXCR4—Disease—HLA-A—hematologic cancer	3.58e-05	0.000277	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—PIK3CG—hematologic cancer	3.57e-05	0.000276	CbGpPWpGaD
Framycetin—Nausea—Doxorubicin—hematologic cancer	3.57e-05	0.000268	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—PTPN1—hematologic cancer	3.56e-05	0.000275	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—PTPN11—hematologic cancer	3.51e-05	0.000272	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—RASGRP1—hematologic cancer	3.5e-05	0.000271	CbGpPWpGaD
Framycetin—CXCR4—Disease—PDGFB—hematologic cancer	3.49e-05	0.00027	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—SYK—hematologic cancer	3.49e-05	0.00027	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—HSP90AA1—hematologic cancer	3.49e-05	0.00027	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—PIK3CD—hematologic cancer	3.46e-05	0.000268	CbGpPWpGaD
Framycetin—CXCR4—Disease—TSC2—hematologic cancer	3.41e-05	0.000264	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—CREB1—hematologic cancer	3.4e-05	0.000263	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—STAT1—hematologic cancer	3.36e-05	0.00026	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—CCL2—hematologic cancer	3.33e-05	0.000257	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—IL6R—hematologic cancer	3.32e-05	0.000257	CbGpPWpGaD
Framycetin—CXCR4—Disease—FGFR3—hematologic cancer	3.28e-05	0.000254	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—PIK3R1—hematologic cancer	3.27e-05	0.000253	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—JAK2—hematologic cancer	3.18e-05	0.000246	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—MAP2K1—hematologic cancer	3.16e-05	0.000245	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—GRB2—hematologic cancer	3.15e-05	0.000243	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—PIK3CD—hematologic cancer	3.14e-05	0.000243	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PDGFA—hematologic cancer	3.14e-05	0.000243	CbGpPWpGaD
Framycetin—CXCR4—Disease—BAD—hematologic cancer	3.11e-05	0.000241	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—KITLG—hematologic cancer	3.09e-05	0.000239	CbGpPWpGaD
Framycetin—CXCR4—Disease—NOTCH1—hematologic cancer	3.08e-05	0.000238	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—STAT5A—hematologic cancer	3.02e-05	0.000234	CbGpPWpGaD
Framycetin—CXCR4—Disease—CD80—hematologic cancer	3.02e-05	0.000234	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—PIK3CB—hematologic cancer	3.02e-05	0.000233	CbGpPWpGaD
Framycetin—CXCR4—Disease—KIT—hematologic cancer	3.01e-05	0.000233	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CDKN2B—hematologic cancer	3e-05	0.000232	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—PIK3R1—hematologic cancer	2.97e-05	0.00023	CbGpPWpGaD
Framycetin—CXCR4—Disease—PTPN11—hematologic cancer	2.96e-05	0.000229	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CD86—hematologic cancer	2.9e-05	0.000224	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—JAK2—hematologic cancer	2.88e-05	0.000223	CbGpPWpGaD
Framycetin—CXCR4—Disease—CREB1—hematologic cancer	2.87e-05	0.000222	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—HES1—hematologic cancer	2.86e-05	0.000221	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—NCOR1—hematologic cancer	2.84e-05	0.00022	CbGpPWpGaD
Framycetin—CXCR4—Disease—BRAF—hematologic cancer	2.83e-05	0.000219	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CSF2—hematologic cancer	2.81e-05	0.000217	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—FGF1—hematologic cancer	2.81e-05	0.000217	CbGpPWpGaD
Framycetin—CXCR4—Disease—IL6R—hematologic cancer	2.8e-05	0.000217	CbGpPWpGaD
Framycetin—CXCR4—Disease—CREBBP—hematologic cancer	2.8e-05	0.000216	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—FOXO1—hematologic cancer	2.77e-05	0.000214	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—IL2—hematologic cancer	2.77e-05	0.000214	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PDGFRB—hematologic cancer	2.77e-05	0.000214	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—PIK3CB—hematologic cancer	2.74e-05	0.000212	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PDGFRA—hematologic cancer	2.72e-05	0.000211	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—JAK1—hematologic cancer	2.71e-05	0.00021	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PRKCG—hematologic cancer	2.71e-05	0.00021	CbGpPWpGaD
Framycetin—CXCR4—Disease—MAP2K1—hematologic cancer	2.67e-05	0.000206	CbGpPWpGaD
Framycetin—CXCR4—Disease—PIK3CD—hematologic cancer	2.65e-05	0.000205	CbGpPWpGaD
Framycetin—CXCR4—Disease—FGF2—hematologic cancer	2.54e-05	0.000196	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—IL2RA—hematologic cancer	2.53e-05	0.000196	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—IL2—hematologic cancer	2.51e-05	0.000195	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—TERT—hematologic cancer	2.51e-05	0.000194	CbGpPWpGaD
Framycetin—CXCR4—Disease—PIK3R1—hematologic cancer	2.5e-05	0.000194	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PDGFB—hematologic cancer	2.45e-05	0.000189	CbGpPWpGaD
Framycetin—CXCR4—Disease—JAK2—hematologic cancer	2.43e-05	0.000188	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—TSC2—hematologic cancer	2.39e-05	0.000185	CbGpPWpGaD
Framycetin—CXCR4—Disease—MDM2—hematologic cancer	2.37e-05	0.000184	CbGpPWpGaD
Framycetin—CXCR4—Disease—PIK3CB—hematologic cancer	2.31e-05	0.000179	CbGpPWpGaD
Framycetin—CXCR4—Disease—MTOR—hematologic cancer	2.31e-05	0.000179	CbGpPWpGaD
Framycetin—CXCR4—Disease—CD4—hematologic cancer	2.31e-05	0.000178	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—FGFR3—hematologic cancer	2.3e-05	0.000178	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MAPK14—hematologic cancer	2.28e-05	0.000176	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—ESR1—hematologic cancer	2.23e-05	0.000173	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—FN1—hematologic cancer	2.21e-05	0.000171	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—NFKBIA—hematologic cancer	2.18e-05	0.000169	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—BAD—hematologic cancer	2.18e-05	0.000169	CbGpPWpGaD
Framycetin—CXCR4—Disease—CDKN1B—hematologic cancer	2.17e-05	0.000168	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—NOTCH1—hematologic cancer	2.16e-05	0.000167	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CD80—hematologic cancer	2.11e-05	0.000164	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PIK3CG—hematologic cancer	2.11e-05	0.000163	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—KIT—hematologic cancer	2.11e-05	0.000163	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—NRAS—hematologic cancer	2.11e-05	0.000163	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PTPN11—hematologic cancer	2.07e-05	0.00016	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—MAPK3—hematologic cancer	2.02e-05	0.000156	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CREB1—hematologic cancer	2.01e-05	0.000155	CbGpPWpGaD
Framycetin—CXCR4—Disease—CDKN1A—hematologic cancer	2e-05	0.000155	CbGpPWpGaD
Framycetin—CXCR4—Disease—PTEN—hematologic cancer	2e-05	0.000154	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—BRAF—hematologic cancer	1.98e-05	0.000154	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CCL2—hematologic cancer	1.97e-05	0.000152	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—IL6R—hematologic cancer	1.96e-05	0.000152	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CREBBP—hematologic cancer	1.96e-05	0.000151	CbGpPWpGaD
Framycetin—CXCR4—Disease—EP300—hematologic cancer	1.9e-05	0.000147	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MAP2K1—hematologic cancer	1.87e-05	0.000145	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PIK3CD—hematologic cancer	1.86e-05	0.000144	CbGpPWpGaD
Framycetin—CXCR4—Disease—SRC—hematologic cancer	1.85e-05	0.000143	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—PIK3CA—hematologic cancer	1.84e-05	0.000142	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—KRAS—hematologic cancer	1.82e-05	0.000141	CbGpPWpGaD
Framycetin—CXCR4—Disease—STAT3—hematologic cancer	1.79e-05	0.000138	CbGpPWpGaD
Framycetin—CXCR4—Disease—NRAS—hematologic cancer	1.78e-05	0.000138	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—FGF2—hematologic cancer	1.78e-05	0.000137	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PIK3R1—hematologic cancer	1.75e-05	0.000136	CbGpPWpGaD
Framycetin—CXCR4—Disease—MAPK3—hematologic cancer	1.71e-05	0.000132	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—JAK2—hematologic cancer	1.7e-05	0.000132	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—PIK3CA—hematologic cancer	1.67e-05	0.000129	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MDM2—hematologic cancer	1.66e-05	0.000129	CbGpPWpGaD
Framycetin—CXCR4—Disease—MYC—hematologic cancer	1.66e-05	0.000128	CbGpPWpGaD
Framycetin—CXCR4—Disease—TGFB1—hematologic cancer	1.65e-05	0.000128	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MTOR—hematologic cancer	1.62e-05	0.000125	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PIK3CB—hematologic cancer	1.62e-05	0.000125	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—HRAS—hematologic cancer	1.54e-05	0.000119	CbGpPWpGaD
Framycetin—CXCR4—Disease—KRAS—hematologic cancer	1.53e-05	0.000119	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CDKN1B—hematologic cancer	1.52e-05	0.000117	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—AKT1—hematologic cancer	1.5e-05	0.000116	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CASP3—hematologic cancer	1.49e-05	0.000115	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—IL2—hematologic cancer	1.49e-05	0.000115	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—IL6—hematologic cancer	1.48e-05	0.000114	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CCND1—hematologic cancer	1.45e-05	0.000112	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—JUN—hematologic cancer	1.45e-05	0.000112	CbGpPWpGaD
Framycetin—CXCR4—Disease—PIK3CA—hematologic cancer	1.41e-05	0.000109	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CDKN1A—hematologic cancer	1.4e-05	0.000108	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PTEN—hematologic cancer	1.4e-05	0.000108	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MAPK8—hematologic cancer	1.37e-05	0.000106	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—AKT1—hematologic cancer	1.36e-05	0.000105	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—EP300—hematologic cancer	1.33e-05	0.000103	CbGpPWpGaD
Framycetin—CXCR4—Disease—HRAS—hematologic cancer	1.3e-05	0.000101	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—SRC—hematologic cancer	1.3e-05	0.0001	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—VEGFA—hematologic cancer	1.26e-05	9.77e-05	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—STAT3—hematologic cancer	1.25e-05	9.67e-05	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—NRAS—hematologic cancer	1.25e-05	9.65e-05	CbGpPWpGaD
Framycetin—CXCR4—Disease—IL6—hematologic cancer	1.25e-05	9.65e-05	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MAPK3—hematologic cancer	1.19e-05	9.24e-05	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MYC—hematologic cancer	1.16e-05	8.99e-05	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—TGFB1—hematologic cancer	1.16e-05	8.96e-05	CbGpPWpGaD
Framycetin—CXCR4—Disease—AKT1—hematologic cancer	1.15e-05	8.9e-05	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—KRAS—hematologic cancer	1.07e-05	8.3e-05	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PIK3CA—hematologic cancer	9.86e-06	7.63e-05	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—TP53—hematologic cancer	9.54e-06	7.38e-05	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—HRAS—hematologic cancer	9.12e-06	7.06e-05	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—IL6—hematologic cancer	8.73e-06	6.76e-05	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—AKT1—hematologic cancer	8.06e-06	6.23e-05	CbGpPWpGaD
